Peptide vaccine trials for melanoma: preclinical background and clinical results.
Talebi
Tony
T
Department of Medicine, Keck/USC School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA.
Weber
Jeffrey S
JS
D000951:Antigens, Neoplasm; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D008545:Melanoma / Q000276:immunology* / Q000628:therapy*; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins / Q000276:immunology*; D012878:Skin Neoplasms / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*; D022223:Vaccines, Subunit / Q000276:immunology*
D000951:Antigens, Neoplasm; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D022223:Vaccines, Subunit